ASCO 2019: Paradigm shift in treatment of metastatic cutaneous squamous cell carcinoma

Michael R. Migden | | Juni 6, 2019

Föreläsare: Michael R. Migden

In this MEDtalk Michael R. Migden report from a 12-month follow-up study from a primary analysis of cemiplimaba human monoclonal anti-pd-1, in patients with metastatic cutaneous squamous cell carcinoma.  Objective response rate was 49.2% and median progression-free survival was 18.4 months. According to Michael R. Migden are cemiplimab a paradigm shift in treatment of these group of patients.